ClinicalTrials.gg
RecruitingNCT05977686AnemiaPOCUpdated Oct 15, 2026

Hemoglobin Testing in Pregnant Patients

An observational study in Post Partum Hemorrhage and Anemia of Pregnancy, sponsored by Inova Health Care Services. Recruiting at 2 sites in United States. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Inova Health Care Services · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 15, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Postpartum Hemorrhage with a site in United States — 10 open to participants now, 12 under way, 3 of them phase 3. Postpartum Hemorrhage · United States.

Planned enrollment
7th of 18
250 · median 108
Started
2025
with 6 others
Observational
18 of 65
4 open now
Primary completion
2027-09
later than 9 of 11 live
Registered
54th of 65
by date
Lead sponsor
2 of 65
Inova Health Care Services

Among the 65 studies in Postpartum Hemorrhage with a site in United States, this one is the 7th largest by planned enrollment of the 18 observational ones that give a count, is one of 7 that started in 2025, is one of 18 observational ones, reaches primary completion later than 9 of the 11 other live ones, and was the 54th registered.

Postpartum Hemorrhage

471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.

Browse Postpartum Hemorrhage studies →

Open to participants now

10 of the 65 studies in Postpartum Hemorrhage with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Postpartum Hemorrhage with a site in United States, or all of them as a file.
02

Study summary

The project is a prospective observational study aimed to assess and to validate the use of point-of-care hemoglobin testing in pregnancy. Point-of-care hemoglobin testing has the potential to (1) increase access to hemoglobin monitoring in pregnancy in low resource settings, (2) increase availability of hemoglobin monitoring in anemic patients, and (3) provide immediate results for real-time patient counseling and intervention. However, to date, point-of-care hemoglobin testing devices have not yet been studied for use in an ambulatory obstetric population. The Masimo device is a Root Radical 7 Pulse CO-Oximeter, manufactured by Masimo, Inc. This device is non-invasive and placed externally on a patient's finger to generate an estimation of a patient's hemoglobin value. The HemoCue® device is a minimally-invasive device that relies on the finger prick method to get a capillary hemoglobin measurement, and The Rubby is a mobile application based platform that uses a photo of the participants nailbed to estimate hemoglobin values. Participants in this study will be approached at the Obstetrics and Gynecology clinics at George Washington Medical Faculty Associates. Point-of-care hemoglobin measurements will be assessed using the non-invasive Masimo device along with minimally-invasive hemoglobin HemoCue® Hb 801 device and compared to traditional venipuncture hemoglobin testing.

Read the detailed description

This will be a prospective, observational study for which aim to recruit 200 patients over the study period. Patients will be approached at one of the MFA Obstetrics and Gynecology clinics. Once consented, they will be approached at least two time-points during their antenatal care as below:

  1. OB new/ first prenatal visit (usually between 12-18 weeks of gestation)
  2. OB return visit (usually between 24-28 weeks of gestation)

May need to get more Hb time-points readings (up to five readings) if the patient will be diagnosed with anemia at any of the previously mentioned visits or will be scheduled to have more blood draws during the prenatal care period. At each time-point visit, we plan to talk with the provider of the patient about the study. Then the study protocol and the recruitment process with the patient will be discussed. If the patient consents, the researchers will coordinate with the lab personnel the exact time of the routinely ordered blood draw (as a part of the subject's antenatal care) to determine the appropriate time to get the Hb readings using the devices (preferrably, right before the venipuncture). To obtain the readings, a study research coordinator will apply a disposable probe (Rainbow R1 25 adult adhesive sensor) connected to a Radical-7 co-oximeter sensor on the ring finger of the same arm of the venipuncture, shielded by an opaque covering to eliminate intereference from ambient light to obtain the SpHb reading. In addition, during in the same setting, we will ask for a finger prick capillary sample to get the Hemocue Hb reading as well (the same side will be used). Both readings will be tabulated in a case report form and the standard lab hemoglobin reading will be added to them once received. This is how it will validate the performance of the Masimo and the Hemocue devices with the routine lab test results. Additionally, the researchers will collect demographics, procedure-specific and some antenatal-care variables including vitals, gestational age and the exact date and time of the records at each time point visit, using a well-structured case report form.

03

Conditions studied

  • Post Partum Hemorrhage
  • Anemia of Pregnancy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Pregnant women ages 18-50 years old

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women ages 18-50 years old

Exclusion criteria

Exclusion Criteria:

  • Patients with hemoglobinopathies (qualitative defects, sickle-cell anemia) and synthesis disorders (quantitative defects such as thalassemia)
  • Patients with peripheral vascular diseases and skin conditions that affect blood vessels in the digit
  • Patients with hyperbilirubinemia
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No

Interventions

  • DeviceMasimo Root Radical 7 Pulse CO-Oximeter

    The Masimo device is non-invasive and placed externally on a patient's finger to generate an estimation of a patient's hemoglobin value.

  • DeviceHemoCue Hb 801

    The HemoCue® device is a minimally-invasive device that relies on the finger prick method to get a capillary hemoglobin measurement.

06

What researchers measure

Primary outcomes

  1. Validity of each POC device to detect anemia

    Sensitivity, specificity, and positive and negative predictive values for each POC device to detect anemia (Hgb \< 11mg/dL) or severe anemia (Hgb \< 9mg/dL).

    Time frame: Within 6 hours of CBC draw

  2. To determine if Point of Care Hemoglobin testing correlates to clinical laboratory results.

    Verify the correlation between point-of-care hemoglobin/ferritin values and the reference laboratory hemoglobin from a CBC (complete blood count) and clinical ferritin test. This aim will help us determine the suitability of the selected testing methods.

    Time frame: 24 - 48 hours to get all test results

07

Study locations

1 of 2 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Sep 2027, 21 months after the start.

Of 38 non-industry observational studies under Postpartum Hemorrhage, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's planned 21 months is below that.

Counting every sponsor, half of 42 studies reached it within 21 months; a quarter within 9 and three quarters within 38.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Sep 2026 → Sep 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2023
First posted
Aug 4, 2023
StartActual
Dec 3, 2025
Primary completionEst.
Sep 2027was Sep 2026
CompletionEst.
Dec 2027was Dec 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Sep 2027
Oct 15, 2026
Study completion
Dec 2026→Dec 2027
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Primary completion Sep 2026→Sep 2027
    Study completion Dec 2026→Dec 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05977686
Lead sponsor
Inova Health Care Services
Responsible party
Sponsor
First posted
Aug 4, 2023
Start date
Dec 3, 2025
Primary completion
Sep 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Jaclyn Phillips, MD
Contact
japhillips@mfa.gwu.edu
2027412500
Homa Ahmadzia, MD/MPH
Contact
Homa.ahmadzia@inova.org
7036226524
Homa Ahmadzia, MD/MPH
principal investigator · Inova Health Care Services

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion